title: Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia.
abstract: Tamsulosin, a uroselective alpha(1A)-adrenergic-receptor antagonist, has been shown to improve lower urinary tract symptoms associated with benign prostatic hyperplasia. It has a better side effect profile than earlier alpha-adrenergic-receptor antagonists, which were initially developed as antihypertensive agents. Clinical trials of 1 year or longer with tamsulosin show high tolerability for the 0.4 mg dose and no significant interaction with other antihypertensive medications.
authors.forename: Franklin C
authors.initials: FC
authors.lastname: Lowe